BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$398.67M, compared with -$244.58M a year earlier.
Context
- Retained earnings amounted to 95.5% of total assets at the end of Q1 FY2026, down 67.8 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -63.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (356.57M) USD
- Year-over-year change
- -9451.4%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (356.57M) | -9451.4% |
| FY2024 | 2024-12-31 | (3.73M) | -4114.9% |
| FY2023 | 2023-12-31 | (88.57K) | -88.9% |
| FY2022 | 2022-12-31 | (46.88K) | -8.1% |
| FY2021 | 2021-12-31 | (43.36K) | — |
Retained Earnings vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -63.0% is the lowest of 10, against a peer median of -16.4%.
- Retained earnings amounts to 95.5% of total assets for BBOT, versus a peer median of 169.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | Sep 2026 | -$215.51M USD | -37.7% | — | 34.8% |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | -$398.67M USD | -63.0% | — | 95.5% |
| Mar 2026 | -CHF 412.13M CHF | -29.3% | — | 169.4% | |
| Aug 2026 | -$630.13M USD | +31.9% | — | 52.7% | |
| Sep 2026 | -$772.4M USD | -36.9% | — | 74.7% | |
| Mar 2026 | -$825.44M USD | -3.4% | — | 250.4% | |
| Jun 2026 | -$946.6M USD | -20.9% | — | 130.6% | |
| Mar 2026 | -$983.29M USD | -15.7% | — | 387.6% | |
| Mar 2026 | -$1.51B USD | -11.6% | — | 496.4% | |
| Sep 2026 | -$1.75B USD | -16.4% | — | 835.1% | |
| Peer median (excluding BBOT) | — | -16.4% | — | 169.4% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.